Abstract OT-13-04: Solti-1716. Targeting non-Luminal disease by PAM50 with pembrolizumab + paclitaxel in Hormone Receptor-positive/HER2-negative advanced/metastatic breast cancer patients who have progressed on or after CDK 4/6 inhibitor treatment (TATEN trial)
Year: 2021
Type: conference-abstract
Source: Cancer Research
Institutions: Hospital Universitario 12 De Octubre, Solti, Hospital Clínic de Barcelona, Hospital Clínico Universitario de Valencia, Hospital Quirónsalud Sagrado Corazón, Vall d'Hebron Hospital Universitari, Vall d'Hebron Institute of Oncology, Institut Català d'Oncologia, Duran i Reynals Hospital, Fundación Instituto Valenciano de Oncología, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Universitat de Barcelona
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W3132367902